Back to catalogue
SCLP

Scancell Holdings PLC

Health Care First-pass screen £145m
310/1000 Overall fit
AI beneficiary 35% 30
Operating leverage 25% 36
Valuation 25% 30
Downside protection 15% 25

First-pass take

Pre-revenue immuno-oncology biotech with positive Phase 2 melanoma data but zero AI exposure. Material going-concern uncertainty, net-debt position (£3.8M shareholders' deficit), and 8–9 month cash runway (to Q2/Q3 2026) create severe downside risk. No strategic AI angle evident.

Flags

ai-negativeloss-makinggoing-concernnet-debtclinical-stagecash-burnno-valuation-dataregulatory-risk